MedTrace Logo

Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series

NCT01343485 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2018-06-26

Study results available
· View outcomes & findings →

Summary

Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus (HPV) vaccine doses among young women ages 19 to 26. This descriptive and interventional study will provide data to assess impact of a computerized tool upon HPV vaccine series completion. The interventional aspect of this study includes determination of patient assistance and provider support programs applicable to each woman's situation as well as the implementation of a computer software system for customized patient reminders.

Conditions

  • GARDASIL Vaccination

Interventions

BEHAVIORAL

Computer reminder system

Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series

Sponsors & Collaborators

Principal Investigators

  • Ashlesha Patel, MD, MPH · Planned Parenthood Federation of America, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01343485 on ClinicalTrials.gov